ArticleCarcinogenesis2007
Overexpression of iron regulatory protein 1 suppresses growth of tumor xenografts.
Article in Carcinogenesis, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 56 citations in OpenAlex.
- Iron and the lung: emerging roles of iron metabolism in pulmonary disease pathogenesis and therapy.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Emerging dual role of ferroptosis in lung cancer (Review).Oncology reports · 2025Review
- IRP1 mediated ferroptosis reverses temozolomide resistance in glioblastoma via affecting LCN2/FPN1 signaling axis depended on NFKB2.iScience · 2023Article
- Kinetic and Regulatory Properties ofInternational journal of molecular sciences · 2023Article
- Iron regulatory proteins: players or pawns in ferroptosis and cancer?Frontiers in molecular biosciences · 2023Review
- Genome-Wide Identification of the Aconitase Gene Family in Tomato (International journal of molecular sciences · 2022Article
- ACO1 and IREB2 downregulation confer poor prognosis and correlate with autophagy-related ferroptosis and immune infiltration in KIRC.Frontiers in oncology · 2022Article
- ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1.Nature cancer · 2022Article
- Ferroptosis and Its Potential Role in Lung Cancer: Updated Evidence from Pathogenesis to Therapy.Journal of inflammation research · 2021Review
- Iron: An Essential Element of Cancer Metabolism.Cells · 2020Review
- Distinct TP53 Mutation Types Exhibit Increased Sensitivity to Ferroptosis Independently of Changes in Iron Regulatory Protein Activity.International journal of molecular sciences · 2020Article
- Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology.Frontiers in oncology · 2020Review
- p53 tumor suppressor and iron homeostasis.The FEBS journal · 2019Review
- A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2BMC cancer · 2018Article
- Iron in the Tumor Microenvironment-Connecting the Dots.Frontiers in oncology · 2018Review
- Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism.Oncotarget · 2017Article
- Iron deficiency or anemia of inflammation? : Differential diagnosis and mechanisms of anemia of inflammation.Wiener medizinische Wochenschrift (1946) · 2016Review
- MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis.Oncotarget · 2016Article
- Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities.Protein & cell · 2015Review
- IRP2 regulates breast tumor growth.Cancer research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Iron is essential for proliferation of normal and neoplastic cells. Cellular iron uptake, utilization and storage are regulated by transcriptional and post-transcriptional mechanisms. We hypothesized that the disruption of iron homeostasis may modulate the growth properties of cancer cells. To address this, we employed H1299 lung cancer cells engineered for tetracycline-inducible overexpression of the post-transcriptional regulator iron regulatory protein 1 (IRP1). The induction of IRP1 (wild-type or the constitutive IRP1(C437S) mutant) did not affect the proliferation of the cells in culture, and only modestly reduced their efficiency to form colonies in soft agar. However, IRP1 dramatically impaired the capacity of the cells to form solid tumor xenografts in nude mice. Tumors derived from IRP1-transfectants were <20% in size compared to those from parent cells. IRP1 coordinately controls the expression of transferrin receptor 1 (TfR1) and ferritin by binding to iron-responsive elements (IREs) within their mRNAs. Biochemical analysis revealed high expression of epitope-tagged IRP1 in tumor tissue, which was associated with a profound increase in IRE-binding activity. As expected, this response misregulated iron metabolism by increasing TfR1 levels. Surprisingly, IRP1 failed to suppress ferritin expression and did not affect the levels of the iron transporter ferroportin. Our results show that the overexpression of IRP1 is associated with an apparent tumor suppressor phenotype and provide a direct regulatory link between the IRE/IRP system and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.